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ABSTRACT
Restriction fragment length polymorphism
(RFLP) analysis can be used to assess genetic
relatedness of Mycobacterium tuberculosis isolates.
This study reports a collaborative investigation of
false-positive cultures for M. tuberculosis, suspec-
ted when the DNA ﬁngerprint from an index case
matched an epidemiologically improbable source
case. RFLP analysis matched ﬁngerprints in ten of
16 cases of suspected laboratory contamination to
four separate smear-positive sources that were
processed on the same day in the same laboratory.
All single smear-negative, positive cultures pro-
cessed on the same day as smear-positive speci-
mens should be reviewed on a case-by-case basis
to identify possible false-positive cultures.
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A clinical diagnosis of tuberculosis (TB) is,
ideally, conﬁrmed with a positive culture. Even
in cases without symptoms or with a normal
chest radiograph, a positive culture constitutes
an active case in need of treatment, as coloni-
sation with Mycobacterium tuberculosis is not
thought to occur. Recent advances have im-
proved the diagnosis of TB, but have been
associated with a parallel rise in the number of
reports of false-positive cultures [1,2]. Laborat-
ory cross-contamination is a well-documented
source of false-positive cultures, which have
important clinical and public health conse-
quences [3–10]. Diagnostic criteria for suspected
laboratory cross-contamination with M. tubercu-
losis have been published [11,12], and the recent
rise in the number of reports is probably related
to the ease with which these incidents can be
conﬁrmed by molecular epidemiological studies
[13,14]. The present report describes a retrospec-
tive collaborative investigation of four clusters
of false-positive TB cultures caused by probable
laboratory cross-contamination. The investiga-
tion was initiated when the restriction fragment
length polymorphism (RFLP) cluster results for
a case could not be explained by epidemiolog-
ical evaluation.
Between December 2001 and January 2003, 84
M. tuberculosis isolates from 44 patients were
identiﬁed by laboratory culture according to
published guidelines [15,16]. Laboratory contam-
ination was considered if patients had a single
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smear-negative, culture-positive respiratory spe-
cimen, or positive cultures from an unusual site,
or if specimens were processed on the same day
as specimens from a patient with a positive smear
for acid-fast bacilli (AFB). Laboratory contamin-
ation was considered unlikely for patients with
repeatedly positive cultures (n = 24), or for those
who were AFB smear-positive and culture-
positive for M. tuberculosis (n = 1), or if symp-
tomatic, tuberculin skin testing (TST) and
radiology were consistent with active TB (n = 3).
These patients were excluded from further inves-
tigation.
The isolates from the 16 cases in which culture
contamination was suspected were processed for
RFLP analysis using standard methodology for
the IS6110 sequence and standard deﬁnitions
for clustering [17]. Cluster analysis was per-
formed using computer-assisted DNA pattern
recognition software (BioNumerics v. 3.5; Applied
Maths, Sint-Martens-Latem, Belgium). Similarity
measures were calculated using the Dice coefﬁ-
cient, with 1.5% position tolerance, 0.75% opti-
misation, and 0% minimum height and surface.
Complete linkage UPGMA (unweighted pair
group method using arithmetic averages) was
used to develop the dendrogram, with patterns
also veriﬁed visually. The DNA ﬁngerprints of
suspect isolates were compared to the ﬁngerprints
of M. tuberculosis isolates from potential smear-
positive contaminant sources if the processing of
both specimens took place on the same day.
Laboratory contamination was considered un-
likely if the RFLP pattern identiﬁed a unique
DNA ﬁngerprint. For single band differences,
conﬁrmatory typing was performed by multiple
interspersed repetitive units variable number
tandem repeats (MIRU-VNTR) analysis using
standard methodology [18].
Ten cases of laboratory cross-contamination
were identiﬁed among the 16 patients suspected
of having contaminated cultures. The clinical and
laboratory features of these cases are summarised
in Table 1. All patients had an initial negative
smear and yielded a single positive culture. Four
of the ten patients were identiﬁed as probable
cases of contamination and no treatment or
contact investigation was initiated. The six
remaining patients were treated for TB for a
duration of 35–255 days; two of these patients had
medication-related adverse events. Of the 71
named contacts of these six patients, 69 presented
for evaluation at TB Control for 51 TSTs (12 new
positive and 39 negative) and 23 chest radio-
graphs (11 previous positive TSTs and the 12 new
positive TSTs). Four patients accepted treatment
with isoniazid, three of whom received treatment
for 9 months and for latent infection.
Of the 16 isolates ﬁngerprinted, six had a
discordant RFLP pattern compared with the
putative source case, and were thus excluded as
suspect contaminants. RFLP analysis demonstra-
ted matched ﬁngerprints between the suspect
contaminated cultures and four separate
contamination sources in four separate pseudo-
clusters on four separate dates during a
14-month period (Fig. 1). Potential source cases
(A, B, C and D) had AFB smear-positive
Table 1. Clinical and laboratory features of suspected tuberculosis (TB) cases involving laboratory cross-contamination
Patient
TB
symptoms
Clinical
scenario Chest radiograph
TB
skin
test
TB
factor
Initial
process
date
Initial
specimen
Subsequent
specimen
Subsequent
smear and
culture
1 CB Female 50 years None Cirrhosis Bilateral effusions ND None 12 ⁄ 12 ⁄ 2001 Peritoneal ﬂuid ND ND
2 FB Male 76 years Cough ⁄ sputum
fever
Bacterial OM Consolidation ND DM2 CRF 12 ⁄ 12 ⁄ 2001 Spinal aspirate ND ND
3 CB Female 61 years Cough Lung cancer Pleural thickening
hilar fullness
N None 12 ⁄ 12 ⁄ 2001 BAL Sputum 4
4 FB Male 27 years None Post-MVA Upper lobe nodules ND None 12 ⁄ 12 ⁄ 2001 Tracheal aspirate Sputum 2
5a CB Male 87 years None UTI Pleural thickening
healed rib fractures
ND None 05 ⁄ 06 ⁄ 2002 Sputum Sputum 4
6 CB Female 59 years None Post-op surgery Bilateral effusions ND Remote
contact DM2
05 ⁄ 06 ⁄ 2002 Pleural ﬂuid ND ND
7 CB Male 76 years Cough ⁄ sputum
anorexia
COPD Lung cancer Pleural thickening
cavitating mass
N RA on
steroid
18 ⁄ 11 ⁄ 2002 BAL Sputum 4
8 CB Male 59 years Cough Lung cancer Bilateral effusions ND None 18 ⁄ 11 ⁄ 2002 Pericardial ﬂuid ND ND
9 CB Female 43 years None Chronic arthritis Bilateral effusions N None 09 ⁄ 01 ⁄ 2003 Synovial ﬂuid ND ND
10 CB Male 61 years None Post-op surgery Effusion, atelectasis ND None 09 ⁄ 01 ⁄ 2003 Pleural ﬂuid ND ND
aIndex case.
CB, Canadian-born; FB, foreign-born; N, negative; ND, not done; OM, osteomyelitis; DM2, diabetes mellitus type 2; CRF, chronic renal failure; BAL, bronchoalveolar lavage;
MVA, motor vehicle accident; UTI, urinary tract infection; COPD, chronic obstructive pulmonary disease; RA, rheumatoid arthritis.
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respiratory specimens (with large numbers of
organisms) processed on the same dates as the
suspected cases of laboratory contamination. All
source cases had culture-conﬁrmed pulmonary
TB with a fully sensitive organism, and chest
radiographs consistent with active disease. All
but two of the isolates had an identical match
with the RFLP pattern of the possible contam-
inating source. The two remaining isolates
differed from the source by one band, but were
conﬁrmed to be similar by MIRU-VNTR analy-
sis. Despite extensive evaluation, no epidemio-
logical link between the suspected contaminant
cases and members of this cluster could be
identiﬁed.
This is the ﬁrst Canadian report of laboratory
cross-contamination involving multiple pseudo-
clusters conﬁrmed by molecular epidemiology.
Molecular typing of isolates, together with know-
ledge of the local molecular epidemiology, was
invaluable in the recognition of false-positive TB
cultures. Conﬁrmatory typing by MIRU-VNTR
analysis further validated the probability of con-
tamination, despite the single band differences
noted by RFLP analysis. The period that had
elapsed between the processing of the original
specimen and notiﬁcation by the hospital labor-
atory precluded an investigation of all the factors
that might have contributed to potential error.
Despite extensive laboratory investigation, the
exact cause of the cross-contamination events
could not be determined. The four dates on which
cross-contamination occurred were widely separ-
ated and random. Comparison of the RFLP
patterns from the dates when cross-contamination
occurred revealed distinct patterns for each of the
four dates, suggesting that each cross-contamin-
ation event was unique.
Laboratories require a review process to detect
unusual numbers of false-positive cultures and a
mechanism to determine the possible causes. As a
minimum, all smear-negative, single positive
cultures, processed on the same day as a smear-
positive specimen, should be reviewed on a case-
by-case basis to identify possible false-positive
cultures. Since this review was completed, no
cases of laboratory cross-contamination have been
identiﬁed during a 24-month follow-up period.
Ongoing open and timely communication
between clinicians and the laboratory remains
critical in the interpretation of potentially unusual
ﬁndings.
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restriction fragment length poly-
morphism analysis. Cases identiﬁed
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